As of 2024-12-15, the EV/EBITDA ratio of Arcus Biosciences Inc (RCUS) is -4.54. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Arcus's latest enterprise value is 1,317.48 mil USD. Arcus's TTM EBITDA according to its financial statements is -290.00 mil USD. Dividing these 2 quantities gives us the above Arcus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.9x | 14.8x |
| Forward P/E multiples | 15.0x - 15.5x | 15.2x |
| Fair Price | (45.85) - (47.44) | (46.01) |
| Upside | -385.2% - -395.0% | -386.1% |
| Date | EV/EBITDA |
| 2024-12-13 | -4.54 |
| 2024-12-12 | -4.88 |
| 2024-12-11 | -5.14 |
| 2024-12-10 | -4.97 |
| 2024-12-09 | -4.98 |
| 2024-12-06 | -4.92 |
| 2024-12-05 | -4.87 |
| 2024-12-04 | -4.86 |
| 2024-12-03 | -4.66 |
| 2024-12-02 | -4.50 |
| 2024-11-29 | -4.34 |
| 2024-11-27 | -4.45 |
| 2024-11-26 | -4.45 |
| 2024-11-25 | -4.06 |
| 2024-11-22 | -4.11 |
| 2024-11-21 | -3.98 |
| 2024-11-20 | -4.08 |
| 2024-11-19 | -4.05 |
| 2024-11-18 | -4.02 |
| 2024-11-15 | -4.42 |
| 2024-11-14 | -4.45 |
| 2024-11-13 | -4.65 |
| 2024-11-12 | -4.76 |
| 2024-11-11 | -5.07 |
| 2024-11-08 | -5.10 |
| 2024-11-07 | -4.66 |
| 2024-11-06 | -4.43 |
| 2024-11-05 | -4.29 |
| 2024-11-04 | -4.38 |
| 2024-11-01 | -4.36 |
| 2024-10-31 | -4.30 |
| 2024-10-30 | -4.52 |
| 2024-10-29 | -4.65 |
| 2024-10-28 | -4.73 |
| 2024-10-25 | -4.62 |
| 2024-10-24 | -5.10 |
| 2024-10-23 | -4.94 |
| 2024-10-22 | -4.77 |
| 2024-10-21 | -4.82 |
| 2024-10-18 | -5.29 |
| 2024-10-17 | -5.22 |
| 2024-10-16 | -5.10 |
| 2024-10-15 | -5.08 |
| 2024-10-14 | -5.18 |
| 2024-10-11 | -5.27 |
| 2024-10-10 | -4.86 |
| 2024-10-09 | -5.07 |
| 2024-10-08 | -4.98 |
| 2024-10-07 | -4.93 |
| 2024-10-04 | -4.72 |